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Abstract 
Polymorphisms at the rs10994336 and rs9804190 loci of the Ankyrin 3 (ANK3) gene have 
been strongly associated with increased risk for bipolar disorder (BD). However, their 
potential pathogenetic effect on BD-relevant neural circuits remains unknown. We 
examined the effect of BD-risk polymorphisms at rs10994336 and rs9804190 on the working 
memory (WM) circuit using functional magnetic resonance imaging (fMRI) data obtained 
from euthymic patients with BD (n=41), their psychiatrically healthy first-degree relatives 
(n=25) and unrelated individuals without personal or family history of psychiatric disorders 
(n=46) while performing the N-back task. In unrelated healthy individuals, the rs10994336-
risk-allele was associated with reduced activation of the ventral visual cortical components 
of the WM circuit while the rs9804190-risk-allele was associated with inefficient 
engagement of the prefrontal cortical components of the WM. In patients and their healthy 
relatives, risk alleles at either loci were associated with hyperactivation in the ventral 
anterior cingulate cortex. Additionally, Rs9804190-risk-allele carriers with BD evidenced 
abnormal activation within the posterior cingulate cortex. This study provides new insights 
on the neurogenetic correlates of allelic variation at different genome-wide supported BD-
risk associated ANK3 locithat support their involvement in BDand highlight the modulatory 
influence of increased background genetic risk for BD. 
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Introduction 
Allelic variation in the Ankyrin3 (ANK3) gene located on chromosome 10q21.2 has been 
most convincingly associated with increased risk for bipolar disorder (BD). The first report 
concerned a genome-wide association between BD and a single nucleotide polymorphism 
(SNP) at rs9804190 identified in two independent samples from the US and Germany (Baum 
et al., 2008). This association signal within a 70 kilobase region at the 3’ end of the gene was 
later confirmed in a larger study by the Psychiatric GWAS Consortium Bipolar Disorder 
Working Group (Sklar et al., 2011).  Three linked susceptibility loci at rs10994336 (Ferreira et 
al., 2008; Lett et al., 2011; Tesli et al., 2011), rs10994397 (Sklar et al., 2011) and rs1938526 
(Takata et al., 2011; Lee et al., 2011; Dedman et al., 2012) have also been identified within a 
250 kilobase region at the 5’ end of the gene.  The association signals within the 3’ and 5’ 
regions do not overlap and there is no evidence of linkage disequilibrium or other 
interaction between the corresponding SNPs (Schulze et al., 2009). These two regions are 
therefore considered as two independent genetic risk factors for BD.  
The biological mechanisms linking allelic variation in the ANK3 gene to increased risk for BD 
have yet to be clearly defined. The ANK3 gene encodes for multiple protein isoforms of 
Ankyrin-G (AnkG) (Kordeli et al., 1995), a multi-functional protein with several distinct 
domains including spectrin- and trans-membrane binding domains. Brain-specific isoforms 
of AnkG are localized in the nodes of Ranvier and at axonal initial segments (AIS) (Kordeli et 
al., 1995). AnkG is involved in maintenance of neuronal polarity (Rasband, 2010) and in the 
clustering of ion gated channels required for action potential generation and propagation 
(Rasband, 2010; Zhou et al., 1998). Alterations in AnkG sequence or intracellular levels could 
disrupt these mechanisms and affect the function of neural circuits involved in mood and 
cognition. Congruent with this hypothesis, reduced ANK3 expression of brain-specific 
transcripts in mouse models affects AIS throughout the brain (Leussis et al., 2013). These 
mice also exhibit a number of traits considered relevant to BD, specifically increased risk 
taking behaviour (decreased latency in the elevated plus maze and light-dark transition), 
greater reward salience (decreased latency to approach food in the novelty-suppressed 
feeding and increased sucrose preference), and increased reactivity to chronic stress 
(increased forced swim test immobility and elevated baseline and reactive corticosterone 
levels) (Leussis et al., 2013). 
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In human post-mortem samples, the BD-risk-alleles have been associated with reduced 
neuronal ANK3 expression in multiple brain regions (Roussos et al., 2012; Rueckert et al., 
2013). However, in healthy individuals there are significant differences in the phenotypic 
traits associated with allelic variation at the 5’ compared to the 3’ ANK3 region. 
Behaviourally, 5’risk-allele carriers (rs10994336) show increased anxiety-related 
temperamental traits (Roussos et al., 2011) while 3’ risk-allele carriers (rs9804190) show 
abnormalities in psychosis-related traits (Roussos et al., 2012). White matter connectivity is 
reduced in 5’risk-allele carriers (rs10994336) but not in 3’ risk-allele carriers (rs9804190) 
(Linke et al., 2012). In terms of cognitive function, 5’risk-allele carriers (rs10994336), but not 
3’ risk-allele carriers (rs9804190), underperform in tasks of sustained attention and set 
shifting (Linke et al., 2012; Ruberto et al., 2011; Hatzimanolis et al., 2012; Zhang et al., 
2013). The one phenotypic trait shared by risk-alleles in both 3’ and 5’ ANK3 regions is 
working memory disruption (Roussos et al., 2012; Ruberto et al., 2011) which is also a 
documented feature of BD.  
Disruption in working memory (WM) circuitry in BD has been associated both with disease 
expression (Adler et al., 2004; Lagopoulos et al., 2007; Frangou et al., 2008; Townsend et al., 
2010; Jogia et al., 2012; Pomarol-Clotet et al., 2012; Fernández-Corcuera et al., 2013) and 
familial risk (Drapier et al., 2008; Thermenos et al., 2010; Thermenos et al., 2011). Disease 
expression is associated with diminished function in dorsolateral frontoparietal regions 
involved in information encoding and maintenance (Adler et al., 2004; Lagopoulos et al., 
2007; Frangou et al., 2008; Townsend et al., 2010; Jogia et al., 2012; Pomarol-Clotet et al., 
2012; Fernández-Corcuera et al., 2013) and with failure to deactivate the default mode 
network (DMN) as evidenced by aberrant activation within medial prefrontal cortex and the 
anterior cingulate cortex (ACC) (Jogia et al., 2012; Pomarol-Clotet et al., 2012; Fernández-
Corcuera et al., 2013).  The failure to suppress ACC activation during the N-back has also 
been reported in unaffected first-degree relatives of patients and is likely to represent a 
genetically mediated vulnerability trait for BD (Drapier et al., 2008; Thermenos et al., 2010).   
The current study examined the effect of SNP rs10994336 and rs9804190 on the neural 
circuitry subserving WM in a sample of 112 individuals comprising euthymic patients with 
BD (n=41), their psychiatrically healthy first-degree relatives (n=25) and unrelated healthy 
individuals (n=46). The study aimed to identify the neural mechanisms mediating the 
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increased risk for BD conferred by the two independent loci. We tested whether the 
pathogenetic effect of the risk-alleles at rs10994336 and rs9804190 independently 
contribute to failure to suppress DMC activation during the n-back task in patients and their 
healthy relatives, and whether a similar effect would be observed in unrelated individuals 
without a personal or family history of psychiatric disorders.  
Subjects and methods 
Participants 
All participants were selected from the VIBES study cohort which comprises 75 families 
identified through a proband with BD type I and screened to exclude pedigrees with 
schizophrenia or schizophrenia spectrum disorders. Details of the VIBES rationale and design 
have been reported previously (Frangou, 2009). The sample considered in the present study 
comprised 41 euthymic patients with BD, 25 of their psychiatrically healthy first-degree 
relatives, and 46 healthy unrelated individuals, all of white British ancestry (Table 5-1). The 
study received institutional ethical approval. All individuals provided written informed 
consent prior to participation. 
All participants were assessed by trained psychiatrists with patient or non-patient versions 
of the Structured Clinical Interview for Interview (SCID) (First et al., 2002a,b), the Hamilton 
Depression Rating Scale (HDRS) (Hamilton, 1960), the Young Mania Rating Scale (YMRS) 
(Young et al., 1978), the expanded Brief Psychiatric Rating Scale (BPRS) (Lukoff et al., 1986) 
and the Wechsler Adult Intelligence Scale-Revised (WAIS-R) (Wechsler, 1981). Patients 
fulfilled criteria for BD type I based on the Diagnostic and Statistical Manual of Mental 
Disorders, 4th edition, revised (American Psychiatric Association, 1994). We included only 
psychiatrically healthy relatives of BD probands based on the absence of a personal lifetime 
history of any psychiatric disorder. Unrelated healthy individuals without a personal or 
family history of psychiatric disorders were selected to match patients and relatives on age, 
sex, and IQ. 
Exclusion criteria for all participants were current and hereditary neurological disorders, 
DSM-IV lifetime drug or alcohol dependence or drug or alcohol abuse in the preceding six 
months and contraindications to MR imaging. Prior to cognitive and MRI evaluation, 
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patients were required to have been in remission, defined as scoring below 7 in HDRS and 
YMRS, for a minimum of one month based on prospective weekly assessments, and to have 
remained on the same medication type and dose for at least six months. There was a 
significant effect of group on all symptom rating scales (F(2,112)>9.82, p<0.001) with patients 
having higher scores than healthy relatives and unrelated healthy individuals; there was no 
difference between the latter two groups (Table 5-1). The HDRS, YMRS and BPRS were 
highly correlated with each other (all r=0.73, p<0.0001). As only the BPRS is suited for non-
patient populations (healthy relatives and unrelated healthy individuals) this scale was 
chosen to control for psychopathology in subsequent analyses. 
Thirty BD patients were on psychotropic medication; 12 on antipsychotics (7 on atypical, 2 
on typical and 3 on both), 21 on mood stabilisers (lithium =15, sodium valproate=6), and 13 
on selective serotonin reuptake inhibitors. None received anticholinergics or 
benzodiazepines. Medicated and unmedicated BD patients did not differ in age of onset, 
illness duration, IQ, HDRS, YMRS and BPRS total scores (all p> 0.31). 
DNA extraction and genotyping 
DNA was obtained from buccal swabs using conventional procedures. The ANK3 rs10994336 
(risk-allele T) as well as the ANK3 rs9804190 (risk-allele C) genotype were determined by the 
TaqMan allelic discrimination assay (Applied Biosystems, Assay ID C_31344821_10). 
Endpoint analysis was performed using the Applied Biosystems 7900HT Fast Real-Time PCR 
System. Genotypes were called with the SDS 2.3 software and the output was checked 
visually to ensure genotypes fell into distinct clusters. Call rate was 100% as buccal swabs 
were repeated for 7 individuals for whom initial genotyping was undetermined. Accuracy 
was assessed by duplicating 15% of the sample. Reproducibility was 100%.  
Within each group (patients, healthy relatives, unrelated healthy individuals) homozygote 
and heterozygote risk-allele carriers for each SNP were considered as detailed in 
Supplemental Tables 5-S1 and 5-S2. There was no effect of genotype or group-by-genotype 
interaction on age or sex (Tables 5-S1 and 5-S2).  
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Neuroimaging 
Experimental Paradigm: The n-back task was employed in a block design incorporating 
alternating experimental and sensorimotor control conditions. A series of letters in yellow 
font were displayed on a blue screen for two seconds each. Participants were instructed to 
indicate by a button press whether the letter currently displayed matched the letter from 
the preceding n trials. In the sensorimotor control (0-back) condition, the letter “X” was the 
designated target. In the experimental conditions (1, 2, 3-back) the target letter was defined 
as any letter that was identical to the one presented in the preceding one, two, or three 
trials. There were 18 epochs in all, each lasting 30 seconds, comprising 14 letters with a ratio 
of target to non-target letters ranging from 2:12 to 4:10 per epoch. The entire experiment 
lasted 9 minutes and included a total of 49 target and 203 non-target stimuli. To avoid any 
systematic order effects the conditions were pseudo-randomised. Performance was 
evaluated in terms of reaction time to target letters and accuracy (% correct responses). 
Group differences in accuracy were examined using analysis of variance followed by 
pairwise comparisons with Bonferroni correction.  
Acquisition Parameters: Gradient echo planar magnetic resonance (MR) images were 
acquired using a 1.5-Tesla GE Neuro-optimised Signa MR system (General Electric, 
Milwaukee, WI, USA) fitted with 40 mT/m highspeed gradients, at the Maudsley Hospital, 
London. Foam padding and a forehead strap were used to limit head motion. A quadrature 
birdcage head coil was used for radio frequency (RF) transmission and reception. A total of 
180 T2*-weighted MR brain volumes depicting blood-oxygenation level-dependent (BOLD) 
contrast were acquired at each of 36 near-axial planes parallel to the inter-commissural (AC-
PC) plane; repetition time (TR) = 3000ms, echo time (TE) = 40ms, slice thickness = 3mm, 
voxel dimensions = 3.75 x 3.75 x 3.30mm, interslice gap = 0.3mm, matrix size = 64 * 64, flip 
angle=90°. Prior to each acquisition sequence, four dummy data acquisition scans were 
performed to allow the scanner to reach a steady state in T1 contrast. During the same 
session, a high-resolution T1-weighted structural image was acquired in the axial plane for 
subsequent co-registration (inversion recovery prepared, spoiled gradient-echo sequence; 
TR = 18ms, TE = 5.1 ms, TI = 450 ms, slice thickness = 1.5 mm, voxel dimensions = 0.9375 × 
0.9375 x 1.5 mm, matrix size 256 * 192, field of view = 240 x 180 mm, flip angle = 20°, 
number of excitations = 1. 
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Neuroimaging Data Analysis: All analyses were implemented using Statistical Parametric 
Mapping (SPM8) (www.fil.ion.ucl.ac.uk/spm/software/spm8/). The BOLD images were 
realigned to the fifth volume and corrected for interscan movements by means of a rigid 
body transformation with three rotation and three translation parameters. Subsequently, 
the 180 fMRI images were spatially normalized to the standard template of the Montreal 
Neurological Institute (MNI) and re-sampled to a voxel size of 2x2x2mm. Finally, the images 
were smoothed using an 8 mm full-width-half-maximum Gaussian kernel.  
The smoothed single-subject images were analyzed via multiple regression using a standard 
linear convolution model, with vectors of onset representing the 1, 2, 3-back and the 0-back 
condition as the sensorimotor control. Serial correlations were removed using an AR(1) 
model. A high pass filter (128s) was applied to remove low-frequency noise.  
As the effect of any single SNP on neural networks is expected to be subtle, all subsequent 
analyses were restricted to the 3-back condition because (a) individual differences in 
cognitive and neural efficiency are more apparent at high WM load (Gevins and Smith, 
2000), and (b) the effect of diagnosis in patients with BD and their relatives is also most 
consistently seen at high WM load (Jogia et al., 2012; Palaniyappan and Liddle, 2014). 
Images representing the 3-back vs. 0-back contrast from each subject were entered in 
second level random-effects.  
First, we investigated the main effect of each risk-SNP (rs10994336 and rs9804190) and 
their interaction on the WM circuitry in healthy unrelated individuals. This analysis allowed 
us to relate our findings to the literature that has examined the effect of ANK3 only in 
unrelated healthy individuals. Second, full factorial ANCOVA was used to the effect of each 
SNP and their interactions in patients, healthy relatives and unrelated healthy individuals 
with BPRS and accuracy as covariates. Suprathreshold clusters were identified using Family 
Wise Error (FWE) correction of P<0.05. Stereotactic coordinates of the peak maxima of the 
suprathreshold clusters were converted (www.mrc-cbu.cam.ac.uk/Imaging/mnispace.html) 
from the Montreal Neurological Institute spatial array (www.mni.mcgill.ca) to that of 
Talairach and Tournoux (Talairach and Tournoux, 1988). Mean signal change from 
suprathreshold clusters was extracted using the MarsBaR toolbox 
(http://marsbar.sourceforge.net/) and was entered in correlation analyses to examine the 
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effect of age of onset, duration of illness, number of episodes, and medication dose at the 
time of scanning (lithium and antipsychotic). Threshold for statistical significance was set at 
p< 0.005 following Bonferroni correction. 
Results 
Effect of ANK3 allelic variation on clinical features 
Rs10994336 or rs9804190 risk associated patients had significantly higher HDRS, YMRS and 
BPRS scores compared to all other groups (F(2, 112)>6.5, p<0.02) (Supplemental Tables 5-S1 
and 5-S2). There was no effect of genotype on patients’ age of onset, duration of illness and 
number of mood episodes (t39<1.2, p>0.2). 
Effect of ANK3 allelic variation on cognitive task performance 
There was no effect of group, genotype or group by genotype interaction for either SNP on 
general intellectual ability or response time (p>0.1)(Table 5-1, Supplemental Tables 5-S1 and 
5-S2). In contrast, there was a significant effect of group on accuracy for the 3-back 
condition only, where relatives were significantly better than both other groups 
(F(2,112)>24.31, p<0.003)  (Table 5-1). Within the relatives group, non-risk associated relatives 
for either rs10994336 or rs9804190 had significantly higher accuracy (p<0.01) 
(Supplemental Tables 5-S1 and 5-S2).  
Effect of ANK3 allelic variation on WM-related activation in unrelated healthy individuals 
Healthy carriers of the rs10994336 risk-allele showed significantly decreased lateral 
temporal cortical activation within the middle (BA 21) and inferior (BA 20) temporal gyrus 
(Fig. 5-1). In contrast, healthy homozygotes of the rs9804190 risk-allele showed increased 
activation in the lateral prefrontal cortex within the inferior (BA 47/11) and middle (BA 46) 
frontal gyrus (Fig. 5-1). The coordinates of the peak height voxel of the corresponding 
suprathreshold clusters are presented in Table 5-2. 
Effect of ANK3 allelic variation on WM-related activation in BD patients and their healthy 
relatives 
An effect of group (patients, healthy relatives, healthy unrelated individuals) was observed 
in the middle (BA 9 and 10) frontal gyri, in the superior and middle temporal gyri (BA 21/22) 
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and in the ventral ACC (BA 24/32). When compared to unrelated healthy individuals, brain 
activation in patients was significantly (a) reduced in the left (BA 9) and right middle frontal 
gyri (BA 10) and, (b) increased in the superior and middle temporal gyri (BA 21/22) on the 
right and in the ACC bilaterally (BA 24/32). In comparison to patients, healthy relatives had 
greater activation in the middle frontal gyrus bilaterally. No differences were observed 
between unrelated healthy individuals and healthy relatives. The coordinates of the peak 
activations of the suprathreshold clusters are shown in Supplemental Table 5-S3. 
In patients, there were no significant correlations between mean signal change in 
suprathreshold clusters and age of onset, duration of illness, mood episodes or medication 
dose (p> 0.1). 
For the ANK3rs10994336, we found a significant group by genotype interaction in the right 
ventral ACC (x=4, y=19, z=-3, cluster size=35, z-value=3.67) and left ventral posterior 
cingulate cortex (PCC; x=-28, y=-64, z=16, cluster size=166, z-value=4.10). In the right ACC, 
the risk T-allele was associated with increased activation in BD patients and their healthy 
relatives compared to unrelated healthy individuals. In the left PCC, the risk T-allele was 
related with increased activation in BD patients compared to their healthy relatives and to 
unrelated healthy individuals (Fig. 5-2).   
For the ANK3 rs9804190,  a significant group by genotype interaction was found in the right 
ACC (x=4, y=17, z=-4; cluster size= 58; z-value=3.95) in which patients and healthy relatives 
who were risk C-allele homozygotes showed increased activation compared to unrelated 
healthy individuals (Fig. 5-2). 
Discussion 
There are two key findings from this study. First, in healthy individuals without personal or 
family history of psychiatric disorders, the rs10994336 and rs9804190 BD-risk alleles had 
different effects on the working memory (WM) network, although neither affected task 
performance. Second, both BD-risk alleles were associated with failure to deactivate the 
default mode network (DMN) in patients and in their healthy relatives; accuracy was 
reduced in risk-associated healthy relatives.   
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Unrelated healthy carriers of the rs10994336 risk-allele showed reduced engagement of the 
ventral visual cortex within the middle and inferior temporal gyri (Table 5-2). This accords 
with previous reports from two independent samples which found that the largest effect 
size of the rs10994336 risk-allele was on reduced sensitivity in target detection and 
increased errors of commission during the degraded symbol continuous performance task 
(Ruberto et al., 2011; Hatzimanolis et al., 2012). Although the ventral visual cortex is an 
integral part of the WM circuitry, the core WM network involves the frontoparietal cortices 
(Owen et al., 2005; Leech et al., 2011; Rottschy et al., 2012). These regions are also core 
components of the superordinate cognitive control network that supports a broad range of 
executive function tasks (Niendam et al., 2012). Unrelated healthy rs9804190-risk allele 
homozygotes evidenced greater activation within the prefrontal components of the WM 
network although their task performance was comparable to that of the non-risk associated 
unrelated individuals (Table 5-2). This pattern is typically interpreted as evidence of cortical 
inefficiency, and is consistent with behavioural data from an independent sample that also 
found that healthy rs9804190-risk-allele homozygotes underperform in a wide array of 
executive function tasks (Roussos et al., 2012).  
These findings suggest that in the absence of increased background genetic risk for BD or 
other psychiatric disorders the two ANK3 BD-risk loci affect different regions of the WM 
circuitry. The reason for these regional differences is unclear. Available data suggest that 3’ 
risk-alleles (rs9804190) are associated with reduced transcript levels of brain-specific AnkG 
isoforms. To date, the region most commonly implicated is the cerebellum where ANK3 
expression is generally highest (Rueckert et al., 2013). Information about other brain regions 
is incomplete because the available post-mortem studies have limited statistical power due 
to the small number of donors and provide incomplete brain coverage (Roussos et al., 2012; 
Rueckert et al., 2013). With regards to rs10994336, the effect of the risk-allele on ANK3 
expression in the brain is unknown. The rs10994336 polymorphism is located in an intronic 
region (Tesli et al., 2011) but could affect gene expression through cis- or trans-regulatory 
mechanisms (Quinn et al., 2010). Alternatively, rs10994336 may be in strong linkage 
disequilibrium with other, yet unidentified, genetic loci that drive the effects observed here.  
Rs10994336 or rs9804190 risk-associated patients and relatives showed hyperactivity within 
the ventral ACC. The ventral ACC is integral to a network of brain regions involved in affect 
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processing and generation (Critchley et al., 2003) and a key component of the anterior DMN 
(Raichle et al., 2001; Buckner et al., 2008). Activation within the ventral ACC is increased 
during the processing of arousing stimuli or during mental stress (Critchley et al., 2003). The 
n-back task is quite challenging and may engender mild mental stress but it is not expected 
to result in ventral ACC hyperactivation. In fact, deactivation of the ventral ACC is normally 
observed during the n-back task within the context of anticorrelated activity between the 
DMN and the frontoparietal cognitive control network (Leech et al., 2011; Esposito et al., 
2006).  
Accordingly, healthy unrelated individuals in this study showed deactivation of the ventral 
ACC during the n-back task regardless of genotype. As expected, hyperactivation within the 
ventral ACC was observed in the patients regardless of genotype (Jogia et al., 2012; 
Pomarol-Clotet et al., 2012; Fernández-Corcuera et al., 2013) but it was more pronounced in 
rs10994336 or rs9804190 risk associated individuals. Amongst the healthy relatives, ventral 
ACC hyperactivity was only present in risk associated individuals for either risk-allele. 
Additionally, BD carriers of the rs10994336 risk-allele also showed hyperactivity within the 
PCC, centred on the ventral and extending to dorsal regions (Vogt et al., 2006). The PCC has 
dense anatomical connections with multiple cortical and subcortical regions (Hagmann et 
al., 2008) and is a core component of the posterior DMN (Raichle et al., 2001; Buckner et al., 
2008). Healthy individuals performing the n-back task show deactivation in both dorsal and 
ventral PCC (Leech et al., 2011; Esposito et al., 2006) so the persistent PCC activation seen in 
patients suggests that the rs10994336 risk-allele compromises the ability to deactivate this 
brain region.  
Taken together, these findings suggest that aberrant hyperactivation within the ventral ACC 
is a key mechanism mediating the risk-conferring effects of rs10994336 and rs9804190 in 
connection to the WM circuitry. It is noteworthy that this effect appeared to require the 
concomitant presence of additional risk factors for BD as it was not observed in unrelated 
individuals who had no personal or family history of such risk factors. This is consistent with 
the multifactorial pathogenetic model of BD that involves interaction between multiple 
genetic and non-genetic risk factors (Sullivan et al., 2012). The effect of any individual factor 
depends on the relative prevalence of other risk factors that are part of the same 
pathogenetic process. This observation is not unique to ANK3. Consistent with the findings 
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reported here, several neuroimaging studies have shown differential effects of various 
susceptibility polymorphisms (e.g. DISC1, NRG1, COMT) on brain structure and function in 
patients, high-risk groups and unrelated healthy individuals (Addington et al., 2007; Mechelli 
et al., 2008; Prata et al., 2008; Tsuchimine et al., 2013; Narr et al., 2009; Whalley et al., 
2012).  
In conclusion, our results point to a differential effect of BD-risk associated polymorphisms 
at ANK3 rs10994336 and rs9804190 modulated by risk-status for the disorder. This suggests 
that the BD-risk conferring mechanisms associated with these genetic variants are 
influenced by other genetic and possibly non-genetic factors that contribute to risk status. 
Inability to suppress key nodes of the DMN emerged as a common final pathway through 
which either risk-allele may contribute to the pathogenesis of BD. Mood stabilizing 
medications such as Lamotrigine interact with the ANK3 system through ion channels bound 
by AnkG to the axonal initial segment. Our results therefore lend further support to our 
previous study on patients with BD treated with Lamotrigine that showed “normalization” 
of the WM circuitry (Lang et al., 1993; Haldane et al., 2008) and suggest that ANK3-related 
molecular pathways may be a fruitful ground for the identification of new drug targets for 
BD. 
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Table 5-1 Study Sample 
 
 Unrelated Healthy 
Individuals 
N=46 
Patients with BD 
 
N=41 
Healthy Relatives 
 
N=25 
Demographic Variables 
Age(years) 40.3 (13.2) 44.3 (11.9) 39.7 (13.7) 
Sex (Male/Female) 25/21 20/21 13/12 
Clinical Features 
HDRS total score a 0.1 (0.5) 4.8 (5.3) 0.14 (0.4) 
YMRS total score a 0.2 (0.6) 1.4 (3.0) 0.0 (0.0) 
BPRS total score a 24.3 (0.7) 27.5 (4.0) 24.1 (0.4) 
Age of onset (years) n/a 24.7 (8.0) n/a 
Duration of illness (years) n/a 20.2 (10.5) n/a 
Depressive episodes (n) n/a 5.7 (7.5) n/a 
Manic episodes (n) n/a 5.6 (7.7) n/a 
Cognitive task performance  
IQ 112.6 (14.5) 117.9 (17.9) 115.8 (18.5) 
1-back accuracy (% correct) 100 100 100 
1-back response time (sec) 0.6 (0.3) 0.5 (0.2) 0.5 (0.2) 
3-back accuracy (% correct)b 72.1 (17.2) 68.9 (19.7) 90.1 (15.4) 
3-back response time (sec) 0.8 (0.4) 0.8 (0.3) 0.7 (0.2) 
Except for sex, all data are presented as mean (standard deviation); BD= Bipolar Disorder; 
BPRS= Brief Psychiatric Rating Scale; HDRS=Hamilton Depression Rating Scale; YMRS=Young 
Mania Rating Scale. a Patients> healthy individuals and relatives (P<0.001); b Relatives> 
healthy individuals and patients (P=0.003). 
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Table 5-2 Brain regions showing significant effects of allelic variation at 10994336 and 
rs9810490 in the 3-back vs 0-back contrast in unrelated healthy individuals 
Region Gyrus Laterality Brodmann 
Area 
Talairach and 
Tournoux 
Coordinates 
Cluster size z-value 
X y z 
ANK3 rs10994336: Risk-Allele Homozygotes < Non-Risk Allele Carriers   
Temporal Middle 
Temporal 
 
Left  
 
21 
 
-40 
 
 
12 -28 120 3.41 
Right 
 
48 
 
-5 -15 90 3.76 
59 
 
-14 -4 38 3.60 
Inferior 
Temporal  
Left 
 
20 
 
-42 -12 -24 56 3.43 
Right 44 -11 -20 90 3.80 
ANK3 rs9810490: Risk Allele Carriers > Non-Risk Allele Homozygotes  
Frontal  Middle 
Frontal  
Left  
 
46 -40 38 20 46 3.51 
Inferior 
Frontal 
Left  
 
47/10 -46 48 -4 51 3.48 
Suprathreshold clusters significant p<0.05 Family wise correction; x=sagittal; y=coronal; z=axial. 
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Figure 5-1 Effect of genotype on regional brain activation in the 3-back vs 0-back contrast in unrelated healthy individuals. 
All the regions showed are ROIs which I used only for graphical purposes to present brain regions significantly activated 
during the N-back task. 
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Figure 5-2 Effect of genotype on regional brain activation in the 3-back vs 0-back contrast in patients with bipolar disorder and their 
psychiatrically healthy first-degree relatives. 
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Supplemental Material 
Supplemental Table 5-S1 Effect of ANK3 rs10994336 genotype (risk-allele T)  
 Effect of Genotype Effect of Group by Genotype 
Risk 
Associated 
TT+CT 
No-risk 
Associated  
CC 
Risk Associated 
 TT+CT 
No-risk Associated 
CC 
  
 
N = 40 
 
 
 
N = 72 
Unrelated Healthy 
Individuals 
N = 14 
 
 
 
 
 
 
 
 
 
 
BD patients 
 
 N = 16 
Healthy  
Relatives 
 N=10 
Unrelated Healthy 
Individuals  
N = 32 
BD patients 
 
N = 25 
Healthy Relatives 
 
 n=15 
Demographic Variables 
Age(years) 
 
39.9 (13.1) 42.8 (12.28) 40.6 (12.2) 42.0 (10.7) 40.8 (8.3) 39.3 (12.3) 43.3 (12.3) 38.3 (13.7) 
Sex 
(Male/Female) 
 
21/19 34/38 7/7 9/7 4/6 18/14 11/14 7/8 
Clinical Features  
HDRS total score
 a
 2.1 (4.3) 0.5 (0.81) 0.4 (0.9) 5.3 (4.6) 0.3 (0.6) 0.1 (0.4) 1.5 (0.9) 0.1 (0.5) 
YMRS total score 
a 
0.7 (2.1) 0.1 (0.3) 0.2 (0.4) 1.6 (2.9) 0.0 (0.0) 0.2 (0.6) 0.7 (1.4) 0.0 (0.0) 
BPRS total score 
a
 25.6 (3.2) 24.9 (1.0) 24.8 (1.1) 27.3 (4.3) 24.7 (1.1) 24.2 (0.6) 25.9 (1.9) 24.1 (0.3) 
Cognitive Performance 
IQ 117.2  (17.6) 116.9 (16.1) 110.7 (12.9) 112.3 (16.2) 112.0 (20.4) 116.7 (14.5) 121.7 (16.3) 118.3 (18.5) 
3-back accuracy 
(%) 
b, c
 
78.7 (23.1) 66.9 (29.8) 70.5 (19.8) 73.3 (36.5) 83.8 (22.8) 75.1 (24.5) 67.2 (23.5) 90.78 (14.9) 
3-back response 
time (sec) 
0.84 (0.38) 0.77 (0.33) 0.99 (0.37) 0.68 (0.23) 0.54 (0.21) 0.86 (0.46) 0.94 (0.36) 0.75 (0.21) 
Except for sex, all data are presented as mean (standard deviation); BD= Bipolar Disorder; BPRS= Brief Psychiatric Rating Scale; HDRS=Hamilton Depression Rating Scale; 
YMRS=Young Mania Rating Scale. 
a
 BD carriers of the risk-allele > unrelated healthy individuals, relatives, P<0.02; 
b 
relatives> unrelated healthy individuals, P=0.003; 
relatives>  BD Patients, P = 0.003; 
c 
 Group by Genotype Interaction, P = 0.01. 
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Supplemental Table 5-S2 Effect of ANK3 rs9810490 genotype (risk-allele C)   
 
 
 
 
 Effect of Genotype Effect of Group by Genotype 
 Risk 
Associated 
 
CC 
No-risk 
Associated 
 
TT+CT 
 
Risk Associated 
 
CC 
No-risk Associated 
 
TT+TC 
  
 
N = 63 
 
 
N = 49 
Unrelated Healthy 
Individuals  
N = 28 
BD Patients   
 
N = 21 
Healthy 
Relatives 
N = 14 
Unrelated Healthy 
Controls   
 N = 18 
BD Patients  
 
N = 20 
Healthy 
Relatives 
N = 11 
Demographic Variables 
Age(years) 
 
38.8 (13.6) 43.9 (12.1) 40.1 (13.26) 43.5 (12.51) 40.2 (14.3) 40.1 (11.9) 44.8 (9.5) 39.2 (13.8) 
Sex (Male/Female) 
 
29/34 29/20 14/14 8/13 7/7 11/8 12/9 6/5 
Clinical Features 
HDRS total score
 a 
1.7 (3.9) 2.1 (4.1) 0.1 (0.4) 5.5 (5.6) 0.1 (0.1) 1.2 (3.3) 4.5 (5.4) 0.07 (0.3) 
YMRS total score 
a
 0.7 (2.1) 0.5 (1.8) 0.2 (0.5) 2.0 (3.5) 0.0 (0.0) 0.06 (0.25) 1.2 (2.7) 0.0 (0.0) 
BPRS total score 
a
 25.8 (1.5) 25.1 (1.9) 24.3 (0.6) 29.3 (5.0) 
 
24.2 (0.6) 24.7 (1.0) 26.3 (2.7) 24.1 (0.3) 
Cognitive Performance 
IQ 111.8 (15.6) 120.4 (18.7) 117.6 (16.3) 114.1 (13.9) 108.5 (18.1) 119.4 (16.5) 118.3 (21.5) 122.9 (18.1) 
3-back accuracy 
(%) 
 b, c
 
72.02 (25.9) 83.01 (23.1) 67.1 (25.7) 73.5 (30.5) 85.6 (17.0) 85.8 (26.1) 62.5 (23.2) 92.5 (14.2) 
3-back response 
time ( sec)
 
0.76 (0.48) 0.58 (0.42) 0.85 (0.50) 0.61 (0.49) 0.70 (0.37) 0.81 (0.51) 0.41 (0.44) 0.60 (0.29) 
Except for sex, all data are presented as mean (standard deviation); BD= Bipolar Disorder; BPRS= Brief Psychiatric Rating Scale; HDRS=Hamilton Depression Rating Scale; 
YMRS=Young Mania Rating Scale. 
a
 BD carriers of the risk-allele > unrelated healthy individuals, relatives, P<0.02, relatives> unrelated healthy individuals, P = 0.003; relatives>  
BD Patients, P= 0.003; 
c 
Group by Genotype Interaction, P = 0.01. 
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Supplemental Table 5-S3 Brain regions showing significant effect of group in the 3-back vs 0-back contrast  
 
Gyrus Laterality Brodmann Area Talairach and Tournoux Coordinates z-value 
x y Z 
Patients with BD >  Healthy unrelated controls   
Anterior  
Cingulate 
Left  24/32 -14 46 6 3.56 
Right  10 26 -6 3.49 
Superior 
Temporal 
Right  22 54 1 -4 3.93 
Middle 
Temporal 
Right  21 62 -8 -4 4.25 
Patients with BD < Healthy unrelated controls 
Middle Frontal Left 
 
9 -34 14 40 3.70 
Right  10 38 56 -8 3.26 
Patients with BD  < Healthy relatives   
Middle Frontal Left  9 -42 20 34 4.46 
 Right  9 40 32 34 4.01 
Suprathreshold clusters significant p<0.05 Family wise correction; x=sagittal; y=coronal; z=axial. 
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Supplemental Figure 5-S1 Box plot with the mean signal change in the posterior Cingulate 
Cortex in subjects carriying the ANK3 rs10994336. 
 
Supplemental Figure 5-S2 Box plot with the mean signal change in the Anterior Cingulate 
Cortex in subjects carriying the ANK3 rs10994336. 
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Supplemental Figure 5-S3 Box plot with the mean signal change in the posterior Cingulate 
Cortex in subjects carriying the ANK3 rs9810490. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
